Sign In
Buy FATE
$2.45
-0.0600 (-2.39%)
At Close: Jul 31, 2026
7 Small-Cap Stocks to Buy Before the Bull Market Returns
02:15pm, Sunday, 07'th Aug 2022
Small-cap stocks with lower market capitalizations ranging from $300 million to $2 billion have taken quite a hit since January. These stocks typically belong to smaller companies with massive long-te
FATE's Q2 Loss Narrower Than Expected, Pipeline in Focus
12:47pm, Thursday, 04'th Aug 2022
FATE reports a narrower loss and higher collaboration revenues in the second quarter.
Fate Therapeutics Inc. (FATE) CEO Scott Wolchko on Q2 2022 Results - Earnings Call Transcript
10:55am, Thursday, 04'th Aug 2022
Fate Therapeutics Inc. (NASDAQ:FATE ) Q2 2022 Earnings Conference Call August 3, 2022 5:00 PM ET Company Participants Scott Wolchko - President and CEO Ed Dulac - CFO Yu-Waye Chu - Chief Medical Offic
Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates
06:48pm, Wednesday, 03'rd Aug 2022
Fate Therapeutics (FATE) delivered earnings and revenue surprises of 8.14% and 38.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2022 Financial Results
04:01pm, Monday, 25'th Jul 2022
SAN DIEGO, July 25, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the develop
Trial Results Set to Make or Break Small-Cap Pharma Stocks
04:15pm, Wednesday, 06'th Jul 2022
One analyst is putting the odds at three to one that tests of a Karuna Therapeutics Inc. ( KRTX , Financial) schizophrenia drug will meet study objectives, paving the way to Food and Drug Administrati
7 Small-Cap Stocks to Buy in July 2022
08:15am, Monday, 04'th Jul 2022
These are the best small-cap stocks to buy for July 2022. ARCH, AVUV, CEIX, COUR, DVAX, FATE, and TENB can make great investments.
Nkarta Stock a Bargain Compared to Fate Therapeutics
05:24pm, Wednesday, 08'th Jun 2022
Investors who like Fate Therapeutics Inc. ( FATE , Financial) should love Nkarta Inc. ( NKTX , Financial).
Fate: Possible Speedy FDA Approval Process With RMAT Designation
12:52pm, Friday, 03'rd Jun 2022
Meeting with FDA set for mid-2022 to discuss potential to begin pivotal trial using FT516 for patients with relapsed/refractory diffuse large B-cell lymphoma. If all goes well with FDA meeting for FT5
Why Is Fate Therapeutics (FATE) Down 14.1% Since Last Earnings Report?
12:49pm, Friday, 03'rd Jun 2022
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock?
Fate Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference
08:00am, Friday, 03'rd Jun 2022
SAN DIEGO, June 03, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the developm
Fate Therapeutics to Present at Upcoming May Investor Conferences
04:01pm, Friday, 06'th May 2022
SAN DIEGO, May 06, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the developme
FATE's Loss Narrower Than Expected in Q1, Pipeline in Focus
12:03pm, Thursday, 05'th May 2022
FATE reports a narrower loss and higher collaboration revenues in the first quarter.
Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q1 2022 Results - Earnings Call Transcript
11:53pm, Wednesday, 04'th May 2022
Fate Therapeutics, Inc. (NASDAQ:FATE ) Q1 2022 Earnings Conference Call May 4, 2022 5:00 PM ET Company Participants Bob Valamehr - Chief Research & Development Officer Scott Wolchko - Founder, Preside
Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates
06:48pm, Wednesday, 04'th May 2022
Fate Therapeutics (FATE) delivered earnings and revenue surprises of 12.82% and 85.93%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
